Dietmar Berger - 10 Mar 2025 Form 4 Insider Report for GILEAD SCIENCES, INC. (GILD)

Role
Chief Medical Officer
Signature
/s/ Edward S. Son by Power of Attorney for Dietmar Berger
Issuer symbol
GILD
Transactions as of
10 Mar 2025
Net transactions value
$0
Form type
4
Filing time
12 Mar 2025, 18:04:26 UTC
Previous filing
10 Feb 2025
Next filing
05 Jan 2026
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GILD Restricted Stock Unit Award +8,530 +17% 57,505 10 Mar 2025 Common Stock 8,530 Direct F1, F2
transaction GILD Non-qualified Stock Option (Right to Buy) Award $0 +37,710 $0.000000 37,710 10 Mar 2025 Common Stock 37,710 $117.21 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
F2 The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested.
F3 The options have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested.